Overview

Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate

Status:
Completed

Trial end date:
2017-09-20

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the effect of GS-9876 versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) in participants with active RA as measured by change from baseline in Disease Activity Score for 28 joint count using C-reactive protein (CRP) (DAS28 (CRP)) at Week 12.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Methotrexate